Beclomethasone nasal spray doesn't increase IOP

Beclomethasone nasal spray doesn't increase IOP in patients with ocular hypertension and primary open-angle glaucoma, reveals a study in the Journal of Glaucoma.

Dr D. Yuen et al., Department of Ophthalmology and Visual Sciences, Toronto Western Hospital, Toronto, Canada, completed a randomized, double-masked, controlled trial on 19 patients who were randomized to twice-daily beclomethasone versus placebo saline nasal spray.

Four study visits were conducted: baseline, a weeks 2, 4, 6 after starting the nasal spray. The primary outcome measure was IOP and secondary measures were visual acuity, anterior segment changes, patient reported side effects and compliance.

There were no statistically significant differences in baseline characteristics, IOP at each study visit, or change in IOP between the two groups. The mean change in IOP from baseline was +0.50±1.52 versus +0.70±1.44 mm Hg in the steroid and saline nasal spray groups, respectively at the six-week follow-up, concluding that beclomethasone nasal spray does not affect IOP in OHT and POAG patients.

To view the abstract please click here.